MyxoTech. Unlocking microbial dark matter chemistry.

Leverage our exclusive small molecule library for your drug discovery pipeline.

CHEMICAL DIVERSITY FOR A NEW ERA

Our library of natural product chemistry.

The pharmaceutical industry has entered a new era. Novel chemical diversity is needed to address the growing number of identified drug targets.

MyxoTech offers a hyper-organized library of unprecedented microbial dark matter chemistry produced by strains from the phylum Myxococcota.

Employing our Myxo Dark Matter Platform, the library has been systematically built leveraging genomic and metabolomic data to maximize the chemical diversity available to our clients.

Product and Services

MyxoTech makes a novel pool of small molecule chemistry accessible to drug discovery companies. To complement this product, we offer a full menu of services to ensure our client’s natural product preclinical needs are met.

LIBRARY

Access to our library of unprecedented chemistry

ELUCIDATION

Identification and elucidation of the active component

OPTIMIZATION

Drug lead and production yield optimization

This is MyxoTech.

Built through decades of experience in natural product drug discovery.

OUR HISTORY AND MISSION

We are a team of seasoned natural product drug hunters, offering decades of experience and passion for drug discovery from myxobacteria.

Our technology was spearheaded within the Microbial Natural Products (MINS) department headed by Rolf Müller at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and licensed from the Helmholtz Centre for Infection Research (HZI).

The MINS department currently has several patented antimicrobial components in preclinical development. With MyxoTech, the founders are extending the potential of myxobacterial specialized metabolism to indication areas outside of infectious disease.

This is MyxoTech.

Built through decades of experience in natural product drug discovery.

Lorem ipsum dolor sit amet consectetur. Velit orci mi tristique tincidunt at ipsum. Vitae vestibulum amet suspendisse amet vitae natoque sem feugiat sed. Facilisis enim donec amet sit mi duis massa at. Sit adipiscing varius viverra malesuada orci arcu nunc sit viverra. Nulla curabitur felis sagittis euismod.

Lorem ipsum dolor sit amet consectetur. Velit orci mi tristique tincidunt at ipsum. Vitae vestibulum amet suspendisse amet vitae natoque sem feugiat sed. Facilisis enim donec amet sit mi duis massa at. Sit adipiscing varius viverra malesuada orci arcu nunc sit viverra. Nulla curabitur felis sagittis euismod.

Lorem ipsum dolor sit amet consectetur. Velit orci mi tristique tincidunt at ipsum. Vitae vestibulum amet suspendisse amet vitae natoque sem feugiat sed. Facilisis enim donec amet sit mi duis massa at. Sit adipiscing varius viverra malesuada orci arcu nunc sit viverra. Nulla curabitur felis sagittis euismod.

Lorem ipsum dolor sit amet consectetur. Velit orci mi tristique tincidunt at ipsum. Vitae vestibulum amet suspendisse amet vitae natoque sem feugiat sed. Facilisis enim donec amet sit mi duis massa at. Sit adipiscing varius viverra malesuada orci arcu nunc sit viverra. Nulla curabitur felis sagittis euismod.

Lorem ipsum dolor sit amet consectetur. Velit orci mi tristique tincidunt at ipsum. Vitae vestibulum amet suspendisse amet vitae natoque sem feugiat sed. Facilisis enim donec amet sit mi duis massa at. Sit adipiscing varius viverra malesuada orci arcu nunc sit viverra. Nulla curabitur felis sagittis euismod.

The MyxoTech Team

Founding members include (from left to right) Dr. Thomas Hesterkamp(COO), Dr. Ronald Garcia (Founder/Advisor), Dr. Peter Sullivan (CEO), Dr. Olga Kalinina (Founder/Advisor), Dr. Jennifer Herrmann (Founder/Advisor), and Dr. Rolf Müller (CSO). The team brings the multidisciplinary expertise required to carry a natural product through the preclinical phase of drug development.

DR. THOMAS HESTERKAMP

COO

Thomas is a trained human biologist. He spent 15 years in industry, in different companies and roles. His last industry position was EVP Science & Innovation at Evotec. Since 2013 Thomas has been serving the Helmholtz Centre for Infection Research (HZI) and German Center for Infection Research (DZIF) as Head of Product Development. Thomas brings relevant expertise in small molecule drug discovery and early development. He has served numerous collaborations with industry as project manager and/or member of joint steering committees.

DR. RONALD GARCIA

Founder

Ronald is the Head of Microbiology at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and has been with the institute since its inception in 2009. He has spent the last 25 years developing strategies to tap into the phylum Myxococcota’s expansive taxonomic diversity. His innovative techniques have dramatically increased the phylogenetic space available for drug discovery at HIPS and are foundational to MyxoTech. He continues to isolate novel myxobacterial species from diverse environmental samples.

DR. PETER SULLIVAN

CEO

Peter obtained a PhD in pharmacognosy in 2020 from the University of Illinois at Chicago implementing a drug discovery strategy to identify anti-cancer natural products. Additionally, his on-going work has been to comprehensively organize the phylogenetic distribution of natural product chemistry using metabolomics and genomics. Peter has had formative experiences collaborating with Evotec SE and training at natural products drug discovery company Sirenas. Peter has worked as a senior scientist at HIPS since 2021.

DR. OLGA KALININA

Founder

Olga graduated from the Moscow State University in Russia with a degree in mathematics and later completed her PhD in molecular biology at the Engelhardt Institute for Molecular Biology at the Russian Academy of Sciences. She spent her postdoc at the European Molecular Biology Lab and the University of Heidelberg and then joined the Max Planck Institute for Informatics as a junior group leader. Since 2019, Olga has been a research group leader at HIPS and a professor for drug bioinformatics at Saarland University where she has been elucidating the depth of myxobacterial small molecule potential among other activities.

DR. JENNIFER HERRMANN

Founder

Jennifer Herrmann obtained a chemistry degree from Technical University Kaiserslautern followed by earning a PhD in pharmaceutical biotechnology from Saarland University. Jennifer currently leads the biological discovery team at the Department of Microbial Natural Products (MINS) at HIPS focused on translating novel natural product anti-infectives into clinic ready drug leads, including several already patented myxobacterial small molecules. Jennifer brings more than 10 years of experience in screening technologies, compound library management, and profiling of potential new drug candidates in various indications.

DR. ROLF MÜLLER

CSO

Rolf Müller is professor of Pharmaceutical Biotechnology at Saarland University and Managing Director of HIPS. He has authored >600 peer reviewed papers and has an h-index of 96. Rolf has received several awards, including the prestigious Gottfried Wilhelm Leibniz Prize, the PHOENIX Pharmacy Research Award, the DECHEMA Prize, and the Inhoffen Medal. His laboratory has dedicated itself to the exploration of bacterial natural product biosynthetic pathways for almost 20 years. He is the scientific architect of the HIPS pharmaceutical ecosystem that probes myxobacteria to develop anti-infection drug leads.